Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Research Alert: Novo Nordisk Cuts Guidance Amid Impact From Compounded Glp-1s Volume
Research Alert: Some Positive News After A Series Of Setbacks
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
HSBC Initiates Novo-Nordisk A/S(NVO.US) With Buy Rating, Announces Target Price $102
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $64
Research Alert: CFRA Keeps Hold Opinion On Ads Of Novo Nordisk
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
Guggenheim Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating
Novo Nordisk Analyst Ratings
BMO Capital Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating, Cuts Target Price to $64
BNP Paribas Initiates Novo Nordisk at Underperform Rating, $61 Price Target
Novo Nordisk (0QIU) Gets a Sell From Jefferies
BofA Securities Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
Morgan Stanley Maintains Novo-Nordisk A/S(NVO.US) With Hold Rating, Maintains Target Price $99
Berenberg Cuts Novo Nordisk's Price Target on Lower Wegovy Estimates
Novo Nordisk Target Cut to DKK460 From DKK880 by Intron Health
Novo Nordisk Stock Dips as Roche Licenses Rival Weight-Loss Drug
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105